SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Oliver & Co who wrote (2896)11/19/1997 9:25:00 PM
From: T. Mann  Read Replies (2) of 6136
 
Today's AGPH stock movement could be related to the following:

<<High Virological Failure Rate Of HIV Protease Inhibitors Reported

WESTPORT, Nov 19 (Reuters) - German researchers report a 44% virological treatment failure rate in an unselected population of
198 HIV-positive patients treated with protease inhibitors. They believe that this previously unreported high failure rate indicates that
"...the favourable results from controlled studies with antiretroviral drugs containing protease inhibitors cannot simply be translated
into everyday clinical practice." Their findings appear in the November 15th issue of AIDS.

Dr. Bernd Salzberger of the University of Cologne and colleagues conducted a retrospective study in which HIV RNA levels were
evaluated following 6 months of protease inhibitor treatment. "The purpose of this analysis was virological, rather than a
determination of the immunological and clinical response to therapy with protease inhibitors," they explain. Treatment failure was
defined as a less than 1 log10 reduction in HIV RNA from baseline.

By specific protease inhibitor, treatment failure rates were 64% for saquinavir, 38% for ritonavir, and 30% for indinavir. A low CD4
cell count, pretreatment with larger numbers of antiretroviral drugs, and use of saquinavir rather than indinavir or ritonavir were
independent risk factors for virologic treatment failure.

The investigators suggest that future studies focus on "...optimal initial therapy and optimal therapeutic sequences for untreated as
well as for the large number of pretreated patients."

AIDS 1997;11:F113-F-116 >>

T.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News